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Atherosclerosis is characterized by interaction between immune and vascular endothelial cells which is mediated by adhesion
molecules occurring on the surface of the vascular endothelium leading to massive release of proinﬂammatory mediators.
Ginkgo biloba L. (Ginkgoaceae) standardized extracts showing beneﬁcial eﬀects are commonly prepared by solvent extraction,
and acetone is used according to the European Pharmacopoeia recommendations; the well-known Ginkgo biloba acetone extract
EGb761® is the most clinically investigated. However, in some countries, the allowed amount of solvent is limited to ethanol,
thus implying that the usage of a standardized Ginkgo biloba ethanol extract may be preferred in all those cases, such as for food
supplements. The present paper investigates if ethanol and acetone extracts, with comparable standardization, may be
considered comparable in terms of biological activity, focusing on the radical scavenging and anti-inﬂammatory activities. Both
the extracts showed high inhibition of TNFα-induced VCAM-1 release (41.1-43.9 μg/mL), which was partly due to the NF-κB
pathway impairment. Besides ROS decrease, cAMP increase following treatment with ginkgo extracts was addressed and
proposed as further molecular mechanism responsible for the inhibition of endothelial E-selectin. No statistical diﬀerence was
observed between the extracts. The present study demonstrates for the ﬁrst time that ethanol and acetone extracts show
comparable biological activities in human endothelial cell, thus providing new insights into the usage of ethanol extracts in
those countries where restrictions in amount of acetone are present.
1. Introduction
Atherosclerosis is characterized by a massive chronic inﬂam-
mation with increased oxidative stress which in turn induces
the adhesion of immune cells (i.e., monocytes, leucocytes) to
the vascular endothelium and their subsequent migration
into the vessel wall. The interaction between immune and
vascular endothelial cells is mediated by vascular adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), and E-selectin occurring on the surface of the vas-
cular endothelium.
In humans, the expression of adhesion molecules has
been consistently observed in atherosclerotic plaques [1–3],
where high levels of soluble adhesion molecules are consid-
ered useful risk predictors of cardiovascular events in healthy
populations [4]. Their expression can be transcriptionally
regulated by inﬂammatory cytokines such as tumor necrosis
factor-α (TNF-α), which stimulate adhesion molecules
mRNA and cell surface expression through the activation of
NF-κB and AP-1 pathways [5]. These transcription factors
are redox-sensitive and strongly activated by proinﬂamma-
tory and prooxidant mediators, including reactive oxygen
species (ROS).
The expression of adhesion molecules occurring in sev-
eral inﬂammatory models, including TNF-α-induced endo-
thelial inﬂammation, is modulated by the second messenger
cyclic AMP (cAMP) as well [6–8]. Notably, molecules able
to increase cAMP levels, such as the phosphodiesterase
inhibitors (i.e., theophylline), are able to impair leucocyte
adhesion in vascular cells [7, 9–11]. Nowadays, botanicals
exhibiting anti-inﬂammatory mechanisms through cAMP
increase and NF-κB inhibition, other than antioxidant
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activity in endothelial cells, are investigated to counteract the
development of vascular diseases.
Ginkgo biloba L. is an ancient medicinal plant which has
been used in traditional Chinese medicine for thousands of
years. Although both leaves and seeds are currently used as
herbal medicine in China, leaves are considered the unique
source of active principles in many countries, and standard-
ized extracts from leaves are used for supplying pharmaceu-
tical formulations or as ingredient of food supplements.
Phytochemicals occurring in Ginkgo biloba L. leaves
include biﬂavones, terpene trilactones (ginkgolides A, B, C,
J, P, and Q and bilobalide), ﬂavonol glycosides, proanthocya-
nidins, and other polyphenols [12, 13].
Ginkgo biloba leaf extracts show a variety of biological
activities, mostly against cardiovascular [14] and neurologi-
cal diseases, including regulating eﬀects on the entire vascu-
lar system of veins, arteries, and capillaries. Ginkgo biloba
extracts stimulate lipolysis [15], promote metabolism of
brain cells and sensory neurons, and are widely used to treat
memory loss, protect against ROS, and improve mild cogni-
tive impairment and cerebrovascular insuﬃciency [16–19].
Standardized ginkgo extracts should contain ﬂavonoids
(22.0-27.0%), expressed as ﬂavonol glycosides, and 5.0-7.0%
of terpene lactones including ginkgolides A, B, and C and
bilobalide [20], and the daily dose in adults and elderly
should be 240mg according to EMA monograph [21].
Studies in the literature clearly demonstrate that an ade-
quate standardization of the extracts is mandatory for eﬃ-
cacy, and Ginkgo biloba standardized extracts represent the
pharmaceutically used formulations recommended to
achieve beneﬁcial eﬀects.
Ginkgo biloba L. standardized extracts are commonly
prepared by solvent extraction such as water, methanol, eth-
anol, or acetone [22]. European Pharmacopoeia recommends
extraction of Ginkgo powder with acetone twice for 30
minutes [23]. The clinically investigated extract EGb761® is
an acetone Ginkgo biloba extract [24, 25].
In some countries (i.e., Japan), the amount of acetone
allowed in food supplements is limited to ethanol, thus
implying that the usage of standardized ethanol extracts is
mandatory [26]. However, to the best of our knowledge, no
studies have compared the anti-inﬂammatory and antioxi-
dant eﬀects of acetone and ethanol extracts in human endo-
thelial cells, which are considered one of the preferred
biological targets of Ginkgo biloba extracts.
The aim of the present study was (1) to chemically proﬁle
aqueous acetone vs. aqueous ethanol extracts from Ginkgo
biloba leaves similarly standardized to identify diﬀerences
among components; (2) to investigate if both the extracts
may be considered comparable as anti-inﬂammatory and
antioxidant agents; and (3) to elucidate the mode of action
underlying the eﬀect observed in vitro.
2. Materials and Methods
2.1. Plant Material and Extraction. G4E (Ginkgo biloba aque-
ous ethanol extract) and G24 (Ginkgo biloba aqueous acetone
extract, EPG246) were prepared by Linnea SA (Riazzino,
CH) (https://www.linnea.ch/) and provided, as powder, for
biological assays. Ginkgo leaves were collected by plantations
cultivated in Europe and North America under controlled
conditions, according to [27].
For the preparation of Ginkgo biloba G4E, ginkgo leaves
were submitted to solid/liquid extraction using aqueous eth-
anol as extraction solvent. The extracted fractions were then
concentrated under reduced pressure to remove the extrac-
tion solvent and puriﬁed by ﬁltration on resin column and
liquid/liquid extractions. For the preparation of G24, Ginkgo
biloba leaves were submitted to solid/liquid extraction using
aqueous acetone as extraction solvent. The extracted frac-
tions are then concentrated under reduced pressure to
remove the extraction solvent and puriﬁed by liquid/liquid
extractions. In both cases, organic solvent was then replaced
with water and the aqueous phase was ﬁnally concentrated
and dried to obtain the ﬁnal powdered extract.
Patented standardized extraction and puriﬁcation pro-
cesses were applied to obtain extracts with consistent compo-
sition in pharmacologically active compounds.
2.2. HPLC Method for Determination of Flavonoids and
Terpenes. Flavonoids and terpenes occurring in G24 and
G4E were determined according to EP current edition.
Brieﬂy, for ﬂavonoid detection, the extracts (200mg) were
dissolved in methanol (20mL). 15.0mL of diluted hydro-
chloric acid and 5mL of water were added and diluted to
50mL with methanol. 10mL of the previous solution was
hydrolyzed in a 100°C water bath for 25 minutes. An aliquot
(10 μL) of solution was injected: detector: spectrophotometer
at 370nm; column size: l = 0 125m, diameter = 4mm; sta-
tionary phase: C18 (5μm); temperature: 25°C; mobile phase:
A: 0.3 g/L of phosphoric acid R adjusted at pH = 2 0; mobile
phase B: methanol; gradient elution: time 0 (min) (A : B
60 : 40), time 1 (A : B 60 : 40), time 20 (A : B 45 : 55), time 21
(A : B 0 : 100), time 25 (A : B 0 : 100); ﬂow rate: 1mL/min.
Quercetin dehydrate was used as reference compound. For
terpene determination, the extract (120mg) was dissolved
in phosphate buﬀer solution (10mL, pH 5.8) by stirring.
Solution was transferred into a column containing 15 g of
kieselguhr. Column was eluted with ethyl acetate (100mL).
Solvent was evaporated and the residue dissolved in 2.5mL
of the mobile phase. An aliquot (100 μL) of solution was
injected: detector: refractometer at 35°C; column size: l =
0 25m, diameter = 4mm; stationary phase: C8 (5μm);
temperature: 25°C; mobile phase: tetrahydrofuran :metha-
nol : water (10 : 20 : 75, v/v); ﬂow rate: 1mL/min. Method
was applied according to the European Pharmacopoeia.
2.3. Cell Culture. Human endothelial cells (HUVECs, CRL-
1730, ATCC, Virginia, USA), which are immortalized cells
with life expectancy of 50-60 doublings according to ATCC
speciﬁcation, were grown at 37° in Ham’s F-12 Kaighn’s
Medium (Ham F12K) (Sigma-Aldrich, Milano, Italy) supple-
mented with 100U penicillin/mL, 100mg streptomycin/mL,
2mM glutamine, and 20% heat-inactivated foetal calf serum
(FCS) (Euroclone S.p.A, Pero, Italy), in a humidiﬁed atmo-
sphere containing 5% CO2. Cells (passage number 2-30) were
treated with the indicated concentration of Ginkgo biloba L.
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extracts or vehicle alone (<0.2% DMSO). Curcumin 10 μM
was used as reference compound.
2.4. Cytotoxicity. The cytotoxicity of the extracts was evalu-
ated by the 3,4,5-dimethylthiazol-2-yl-5-diphenyltetrazo-
lium bromide (MTT) assay, as previously described [28].
2.5. Measurement of Soluble Adhesion Molecules. For the
measurement of soluble ICAM-1, VCAM-1, and E-selectin
adhesion molecules, HUVECs were grown in 24-well plates
(20,000 cells/well) for 72h; cells were treated with the proin-
ﬂammatory stimulus (TNFα at 20 ng/mL) and the extracts
under study for 6 h. Afterwards, the medium was removed
and stored at -20°C until the assays. Soluble ICAM-1,
VCAM-1, and E-selectin were quantiﬁed in the media by
an enzyme-linked immunosorbent assay (ELISA). ICAM-1
was detected by Human ICAM-1 ABTS ELISA development
kit (PeproTech, Rocky Hill, NJ, USA) and E-selectin by Ray-
Bio Human E-Selectin ELISA (RayBiotech, Norcross, USA),
respectively, by measuring in duplicate 200 and 100 μL of
culture medium and following each manufacturer’s instruc-
tion. For VCAM-1, Corning 96-well EIA/RIA plates were
coated with the rabbit anti-human VCAM-1 (100 pg/well)
(PeproTech, USA) overnight at 4°C. After blocking with
BSA, 250μL of samples was transferred into wells at room
temperature for 2 h. The amount of VCAM-1 in the samples
was detected by using biotinylated rabbit anti-human
VCAM-1 antibody (50 pg/well) and streptavidin-HRP-
conjugated protein (PeproTech, USA). The 3,3′,5,5′-tetra-
methylbenzidine (TMB) substrate reaction was measured
by spectrophotometry (signal read: 450nm, 0.1 s), and
human VCAM-1 standard curve, ranging from 0 to
10 pg/mL, was used to quantify VCAM-1 in the samples.
Curcumin (10 μM) was used as reference compound.
2.6. Measurement of Cell Surface Adhesion Molecules by
Flow Cytometry. HUVECs were plated in 6-well plates
(60,000/well) and treated after 48 hours with TNFα
(20 ng/mL) in the presence of Ginkgo biloba extracts (G4E
and G24) for 6 hours. Controls were treated only with the
vehicle (≤0.2%). Cells were then washed once with PBS,
harvested, and spun at 2000×g for 5 minutes. Cells were
stained in 50 μL of PBS with 2% BSA (Sigma-Aldrich) in
the presence of the following antibodies: PE-conjugated
Mouse anti-Human CD106 (VCAM-1) (BD Pharmingen
cod. 555647), APC-conjugated Mouse anti-Human CD54
(ICAM-1) (BD Pharmingen cod. 559771), and PE-Cy-
conjugated Mouse anti-Human CD62E (E-SEL) (BD Phar-
mingen cod. 550040). Cells were incubated with antibodies
for 30 minutes at 4°C in the dark, then washed once in
PBS with 2% BSA (Sigma-Aldrich), spun at 2000×g, and
resuspended in 250μL of PBS/2% BSA. Cells were acquired
with NovoCyte ﬂow cytometer (ACEA Biosciences, San
Diego, CA, USA) and analyzed by NovoExpress software
(ACEA Biosciences).
2.7. Measurement of Gene Expression by qRT-PCR. For
mRNA analysis, HUVECs were seeded in 100mm plates
(5 × 105 cells/10mL) and treated with TNFα (20 ng/mL)
for 6 hours in the presence of Ginkgo biloba extracts (G4E
and G24); mRNA was extracted with RNeasy Mini Kit (Qia-
gen, Milano, Italy) and quantiﬁed by spectrophotometric
analysis at 260nm (NanoDrop ND-100 spectrophotometer,
Euroclone, Italy).
Real-time PCR reactions were performed on 10ng
mRNA/well in the Real-Time System Bio-Rad CFX384
(Bio-Rad, CA, USA) using an iTaq™ Universal SYBR Green
One-Step Kit (Bio-Rad), which allowed mRNA reverse
transcription and cDNA labelling. Ampliﬁcation of the gene
coding for VCAM-1, ICAM-1, or E-selectin (E-SEL)
(Primmbiotech, Cambridge, UK) was assessed. The thermal
cycling protocol required a preliminary step for reverse
transcription at 50°C for 10min, followed by polymerase
activation step (95°C, 5min) and 40 cycles with 95°C dena-
turation step for 10 s and annealing/extension at 60°C for
30 s. All the samples were tested in triplicate, and the relative
expression of genes was calculated by normalizing the
threshold cycle (Ct) of each gene with the Ct of GAPDH
mRNA to correct for variation in RNA loading. The eﬀect
of the extracts on 84 inﬂammatory cytokines and receptor
genes was evaluated by RT2 Proﬁler PCR Array PAHS-
011Z (Qiagen, Milano, Italy).
2.8. Measurement of ROS Production. To evaluate the eﬀect
of the extracts on ROS formation, HUVECs were grown in
black 96-well plates (10,000 cells/well) for 72 hours and then
treated with the extracts for 24 hours. After the treatment,
cells were incubated for 1 h with a ﬂuorescent probe (CM-
H2DCFDA, Invitrogen by Thermo Fisher Scientiﬁc, USA)
and then washed with PBS 1X before the prooxidant stimula-
tion with H2O2 (500 μM for 1 h). The ﬂuorescence of the
internalized probe was read, after a ﬁnal wash with PBS, by
a microplate reader at 535 nm (Wallac Envision, Perkin
Elmer, Waltham MA, USA). Trolox (500μM) or curcumin
(10μM) was used as reference compounds.
2.9. NF-κB Nuclear Translocation. To assess the eﬀect of the
extracts on the NF-κB (p65) nuclear translocation, HUVECs
were plated in 100mm plates at the density of 5 × 105 cells.
After 72 h, cells were treated for 1 h with the proinﬂamma-
tory mediator and the extracts under study. Nuclear extracts
were prepared using Nuclear Extraction Kit from Cayman
Chemical Company (Michigan, USA) and stored at -80°C
until assayed. The same amount of total nuclear proteins
(10 μg/well), quantiﬁed by the Bradford method (Bio-Rad),
was loaded into the wells. NF-κB translocation was measured
by spectroscopy at 450nm, 0.1 s (VictorX3, Perkin Elmer,
Waltham MA, USA). Data were expressed considering as
100% the absorbance related to the cytokine-induced NF-
κB translocation. The results were the means of at least three
experiments performed in duplicate. EGCG 20 μM was used
as reference compound.
2.10. IκBα Phosphorylation. The eﬀect of G4E and G24 on
IκBα phosphorylation was evaluated by IstantOne™ ELISA
(Life Technologies, Carlsbad, USA), using antibodies against
both phosphorylated and unphosphorylated forms of IκBα.
Cells were seeded in 12-well plates (60,000 cells/well) and
incubated with the proteasome inhibitor MG132 5 μM
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Figure 1: Continued.
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(Sigma-Aldrich) for 2 hours, then TNFα (20 ng/mL) and
ginkgo extracts (G4E and G24) were added to cells for
5min; medium was removed and cells lysed for 10min at
RT with 200μL/well of Cell Lysis Mix. Sample lysate was
quantiﬁed for total protein content by Bradford assay. ELISA
was performed in triplicate on 10μg of proteins/well, reading
the absorbance at 450nm (VictorX3, Perkin Elmer, Waltham
MA, USA). Phospho-IκBα measurement was normalized
with the absorbance of the unphosphorylated protein.
2.11. Measurement of Cyclic AMP. HUVECs cultured in
6-well plates and treated 48 hours late (60,000/well) were
lysed with 0.1M hydrochloric acid at RT for 20min. Cells
were collected using a scraper and subjected to centrifugation
at 1000 × g for 10min. The supernatant was transferred into
new tubes and total protein content was evaluated by the
Bradford method. Samples normalized on the total protein
content were diluted 1 : 2 with assay buﬀer and directly used
for evaluation of intracellular cAMP level by cyclic AMP
ELISA kit (Cayman Chemical Company, cod. 581001, Ann
Arbor, MI, USA) according to the manufacturer’s protocol.
Absorbance was measured at a wavelength of 405nm using
an ELISA microplate reader (VictorX3, Perkin Elmer, Wal-
tham MA, USA).
2.12. Statistical Analysis. All data are expressed as mean
± s d of at least three experiments. Data were analyzed
by unpaired one-way analysis of variance (ANOVA)
followed by Bonferroni test by post hoc test. Statistical
analyses were done using GraphPad Prism 6.0 software
(GraphPad Software Inc., San Diego, CA, USA). p < 0 05
was considered statistically signiﬁcant. IC50s were calculated
using the GraphPad Prism 6.0 software.
3. Results and Discussion
3.1. Characterization of Ginkgo biloba Extracts. Figure 1
reports HPLC proﬁles of G4E and G24. The extracts showed
comparable proﬁles in ﬂavonoid analysis, showing peaks
corresponding to quercetin, kaempferol, and isorhamnetin.
Similarly, terpene analysis identiﬁed peaks corresponding
to ginkgolides (A, B, J, and C) and bilobalide in both
the extracts.
Table 1 reports characterization of both G4E and G24
extracts. 20 diﬀerent batches of each extract were analyzed
for total content of ﬂavonol glycosides, proanthocyanidins,
and bilobalide. The extracts showed the same proﬁle in
terms of proanthocyanidins, bilobalide, and ﬂavonoid con-
tent. According to these results, the major classes of constit-
uents occurring in Ginkgo biloba acetone extract, which is
considered the most suitable to provide biological activity,
are also present in the ethanol G4E extract at comparable
concentrations. Standardization was applied as follows:
24% ﬂavone glycosides and 6.0% terpene lactones for both
G24 and G4E.
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Figure 1: HPLC characterization of G4E and G24 extracts. Flavonoids and terpenes occurring in G24 and G4E were determined according to
EP current edition. (a) Flavonoids in G24 extract; (b) ginkgolides and bilobalide in G24 extract; (c) ﬂavonoids in G4E extract; (d) ginkgolides
and bilobalide in G4E extract. G24: acetone extract; G4E: ethanol extract.
Table 1: Characterization of bilobalide, proanthocyanidins, and
ﬂavonoids in ginkgo extracts.
G24 extract G4E extract
% (mean ± s d )
Bilobalide 2 94 ± 0 13 2 87 ± 0 13
Proanthocyanidins 3 62 ± 2 65 4 81 ± 2 42
Flavonol glycosides 25 31 ± 1 04 25 03 ± 0 94
Results are the mean ± s d of 20 diﬀerent batches of G24 (acetone) or G4E
(ethanol) extracts.
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Thus, we performed a panel of experiments to investigate
if similar proﬁles parallel comparable anti-inﬂammatory and
antioxidant activity in human endothelial cells. No cytotoxic-
ity at concentrations used in the present study was observed
in endothelial cells (Figure 2).
3.2. Ginkgo Extracts Inhibit Cell Surface and Adhesion
Molecule Release in Human Endothelial Cells. In the ﬁrst set
of experiments, the ability of the extracts to impair soluble
and cell surface VCAM-1, ICAM-1, and E-selectin in human
endothelial cells was investigated. Results are shown in
Figure 3. Both the extracts inhibited in a concentration-
dependent way adhesion molecule release induced by TNFα;
however, the extracts slightly inhibited membrane ICAM-1
starting from 250 μg/mL (Figure 3, Table 2). Both the
extracts showed higher activity in inhibiting soluble than
the membrane forms. Ginkgo extracts showed higher activity
on soluble VCAM-1 (41.1 and 43.9 μg/mL for G4E and G24
extracts, respectively) whereas the inhibitory eﬀect on
ICAM-1 and E-selectin was less pronounced (Table 2 and
Figure 3). Our ﬁndings agree with previous investigations
by Chen et al., who demonstrated inhibition of adhesion
molecules by a Ginkgo biloba standardized extract provided
by Dr. Schwabe [5], which is considered comparable to
G24 extract.
3.3. Ginkgo Extracts Inhibit NF-κB Pathway in Human
Endothelial Cells. Proinﬂammatory cytokines, such as TNFα,
activate NF-κB pathway leading to expression of a variety of
proinﬂammatory mediators, including adhesion molecules.
Thus, NF-κB activation represents a key regulator of adhe-
sion molecule expression in human endothelial cells. NF-κB
is also known as a redox-sensitive transcription factor
activated by ROS [29], thus showing proinﬂammatory and
prooxidant properties. NF-κB activation mainly occurs via
IκB kinase- (IKK-) mediated phosphorylation of IκBα [30].
Thus, inhibitors of IκBα phosphorylation may impair the
NF-κB pathway leading to an anti-inﬂammatory eﬀect.
To evaluate if the extracts could impair NF-κB activation,
HUVECs were treated with G4E and G24 for 1 hour; then,
nuclear translocation from the cytoplasm into the nucleus
was measured by ELISA, as previously described in Materials
and Methods. Both the extracts inhibited NF-κB transloca-
tion in a concentration-dependent fashion (Figure 4(a)), with
comparable IC50 (75.8 and 79.9 μg/mL for G4E and G24,
respectively). Moreover, the extracts showed a statistically
signiﬁcant decrease of IκBα phosphorylation at 250μg/mL,
leading to a reduced proteasomal degradation of the NF-κB
inhibitor (Figure 4(b)). Interestingly, we observed a signiﬁ-
cant eﬀect on cell surface expression of adhesion molecules
starting from the same concentration (250μg/mL) thus
remarking NF-κB impairment as the main mode of action
of the extracts. Both inhibition of the NF-κB nuclear trans-
location and IκBα phosphorylation was conﬁrmed by west-
ern blot assays (data not shown).
Previous papers reported the eﬀect of Ginkgo biloba
extracts as inhibitors of the NF-κB activation in a variety of
cell lines including endothelial cells [5, 31–33]. Some impor-
tant beneﬁcial eﬀects of EGb761 extract, which is comparable
to G24 for extraction procedure and standardization, are due
to the NF-κB impairment [31]. Our results clearly show that
both G4E and G24 extracts similarly inhibit NF-κB translo-
cation at low concentrations, with the same IC50.
3.4. Ginkgo Extracts Inhibit ROS Production in Human
Endothelial Cells.During inﬂammation, immune cells release
high amount of ROS which induce oxidative stress in endo-
thelial cells. It is widely known that moderate amounts of
ROS have beneﬁcial eﬀects in human health contributing to
ﬁght invasion of pathogens or promoting tissue repair pro-
cesses. Moreover, uncontrolled generation of ROS leads to
reduced levels of endogenous antioxidant enzymes (superox-
ide dismutase, glutathione peroxidase, and catalase), causing
oxidative tissue damage.
To investigate if the extracts may counteract oxidative
stress showing antioxidant properties, HUVECs were treated
with G4E and G24 for 24 hours; thus, cells were incubated
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Figure 2: Ginkgo extracts did not impair HUVEC viability in the experimental conditions. Cytotoxicity was neither exhibited during
treatment with extracts and TNFα for 6 h (a) or treatment with extracts for 24 h (b).
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with a ﬂuorescent probe for one hour. Finally, a typical pro-
oxidant stimulus (H2O2, 500 μM) was added for 1 hour to
increase ROS production in HUVEC.
Both the extracts inhibited ROS production, although the
eﬀect was signiﬁcant only at the highest concentration tested
(Figure 5). Our data agree with previous papers reporting
reduction of ROS production and oxidative stress although
in diﬀerent Ginkgo biloba extracts and cell models [5, 34,
35]. However, this is the ﬁrst report demonstrating that the
inhibitory eﬀect on ROS formation in human endothelial
cells by G4E and G24 is comparable.
3.5. Eﬀect of Ginkgo Extracts on Adhesion Molecule Gene
Expression in Human Endothelial Cells. Since G4E and G24
0
20
40
60
80
100
120
M
ea
n 
flu
or
es
ce
nt
 in
te
ns
ity
(%
 v
s. 
TN
F 훼
) 
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎
TNF훼
G. biloba extract
 (휇g/mL)
−
− −
++ ++ + +
100 250 500 1000
+ + +
100 250 500 1000
(a)
0
20
40
60
80
100
120
E-
SE
L 
re
le
as
e (
%
 v
s. 
TN
F훼
) 
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
−
− −
++ ++ + +
50 100 250 500
+ + +
50 100 250 500
TNF훼
G. biloba extract
 (휇g/mL)
(b)
TNF훼
G. biloba extract
 (휇g/mL)
0
20
40
60
80
100
120
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎⁎⁎⁎
⁎⁎⁎ ⁎⁎⁎
M
ea
n 
flu
or
es
ce
nt
 in
te
ns
ity
(%
 v
s. 
TN
F훼
)
−
− −
++ ++ + +
100 250 500 1000
+ + +
100 250 500 1000
(c)
0
20
40
60
80
100
120
IC
A
M
-1
 re
le
as
e (
%
 v
s. 
TN
F훼
)
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
−
− −
++ ++ + +
50 100 250 500
+ + +
50 100 250 500
TNF훼
G. biloba extract
 (휇g/mL)
(d)
0
20
40
60
80
100
120
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎⁎⁎⁎
⁎⁎⁎
M
ea
n 
flu
or
es
ce
nt
 in
te
ns
ity
(%
 v
s. 
TN
F훼
) 
−
− −
++ ++ + +
100 250 500 1000
+ + +
100 250 500 1000
TNF훼
G. biloba extract
 (휇g/mL)
(e)
0
20
40
60
80
100
120
V
CA
M
-1
 re
le
as
e (
%
 v
s. 
TN
F훼
) 
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
⁎⁎⁎
−
− −
++ ++ + +
0.5 1 10 50
+ + +
100 0.5 1 10
+
50
+
100
⁎⁎⁎
⁎
⁎
TNF훼
G. biloba extract
 (휇g/mL)
(f)
Figure 3: Ginkgo extracts inhibit soluble and cell surface adhesion molecules in human endothelial cells. G4E (grey bars) and G24 (white
bars) similarly inhibited E-selectin (a) and VCAM-1 (e) cell surface expression in human endothelial cells; a slight statistically signiﬁcant
inhibition (20-30%) was observed on ICAM-1 (c) at concentrations starting from 250 μg/mL. The inhibition of the extracts on E-selectin
(b), ICAM-1 (d), and VCAM-1 (f) release was more pronounced. Curcumin 10μM was used as reference inhibitor of adhesion molecules
in all the experiments (average inhibition of 77% for E-selectin, 96% for ICAM-1, and 72% for VCAM-1).
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inhibited soluble and cell surface expression of adhesion mol-
ecules, we assayed mRNA analysis at the same experimental
conditions to verify the eﬀect at transcriptional level.
Interestingly, at 250μg/mL, extracts were able to inhibit E-
selectin (40-50%) and slightly ICAM-1 (10-30%), whereas
VCAM-1 transcription was not aﬀected (Figure 6) thus
suggesting that E-selectin impairment is regulated by
diﬀerent mechanisms with respect to ICAM-1 and VCAM-1.
Collins et al. [36] collected in detail evidences on how
these proteins are regulated at transcriptional level in endo-
thelial cells: NF-κB/IκBα system plays a crucial role in
TNF-α-induced expression of adhesion molecules, but a rel-
atively small number of other transcription factors must
assemble with NF-κB to generate unique transcriptional-
activating complexes. Focusing on E-selectin transcription,
ATF/CRE (cyclic AMP responsive element) cooperates with
NF-κB, thus E-selectin promoter is susceptible to cAMP reg-
ulation. On the other hand, several experiments in HUVECs
demonstrated that an increase in cAMP levels caused by
cAMP analogues or phosphodiesterase type 3 and 4 inhibi-
tors leads to the inhibition of E-selectin and VCAM-1, but
not ICAM-1 membrane expression [7, 10]. On the contrary,
ICAM-1 (both mRNA and surface expression) is upregulated
by persistent cAMP elevation during TNFα-induced endo-
thelial inﬂammation, thus suggesting antiphosphodiesterase
activity as a possible antagonistic mechanism for extracts
displaying NF-κB and ICAM-1 inhibition [37].
Table 2: IC50 of ginkgo extracts on adhesion molecules and NF-κB translocation.
Form
Membrane Soluble Membrane Soluble Membrane Soluble Nuclear
VCAM-1 sVCAM-1 ICAM-1 sICAM-1 E-sel. sE-sel. NF-κB translocation
G4E 476 1 ± 103 7 1 5 ± 2 4 >1000 226 7 ± 27 4 849 1 ± 169 0 159 2 ± 22 7 75 8 ± 19 9
G24 372 4 ± 39 1 1 6 ± 1 6 >1000 152 5 ± 26 8 726 8 ± 160 3 115 9 ± 15 5 79 9 ± 18 3
IC50s (μg/mL) were calculated using GraphPad Prism 6.0 software (GraphPad Software Inc., San Diego, CA, USA). Data represent the mean of at least three
experiments performed in duplicate or triplicate. G24: acetone extract; G4E: ethanol extract.
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Figure 4: Ginkgo extracts inhibit NF-κB pathway in human endothelial cells. G4E (grey bars) and G24 (white bars) inhibited the NF-κB
nuclear translocation induced by TNFα in a concentration-dependent fashion (a). Epigallocatechin-3-O-gallate (EGCG) 20μM was used
as reference compound (51% inhibition). At the highest concentration tested (250 μg/mL), G4E and G24 decrease phosphorylation of the
NF-κB inhibitor IκBα (b). G24: acetone extract; G4E: ethanol extract.
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3.6. Eﬀect of Ginkgo Extracts on Inﬂammatory Cytokine and
Receptor Gene Expression in Human Endothelial Cells. Since
G4E and G24 inhibited the NF-κB pathway in our cell
model, we evaluated the overall ability of the extracts to
impair a panel of genes involved in endothelial inﬂamma-
tion; data are shown in the supplementary material. TNFα
signiﬁcantly overexpressed 25 genes out of 84, among them
10 were expressed in a statistically signiﬁcant way; however,
both the extracts did not decrease the corresponding
mRNA levels, except for the member of the TNF family
TNFSF10, which was slightly reduced by acetonic extract
G24 (Figure S1).
3.7. Ginkgo Extracts Exhibit cAMP-Elevating Activity. To
assess the involvement of cAMP in the anti-inﬂammatory
eﬀect observed in HUVECs, the extracts were tested for their
ability to increase cAMP levels in comparison with the well-
known phosphodiesterase inhibitor theophylline 500 μM at 1
and 6 hours.
Both G4E and G24 (250μg/mL) increased cAMP levels
after 1 and 6 hours (Figure 7) although the eﬀect was
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Figure 6: Eﬀect of ginkgo extracts on adhesion molecules at transcriptional level in human endothelial cells. Ginkgo extracts exhibited a
similar inhibitory eﬀect on transcription of adhesion molecules: at 250μg/mL, G4E (grey bars) and G24 (white bars) showed 50% and
40% inhibition of E-selectin transcription, respectively (a), while VCAM-1 mRNA was not impaired (c); the slight inhibition of ICAM-1
transcription was signiﬁcant only for G4E extract (30% inhibition) (b).
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
2.6
2.8
3.0
In
tr
ac
el
lu
la
r c
yc
lic
 A
M
P
(fo
ld
 v
s. 
TN
F)
 
TNF훼
G. biloba extract
(휇g/mL) 
−
− −
+ +
250
+
250
−
− −
+ +
250
+
250
90
+ +
1 h 6 h
⁎⁎
⁎
⁎
⁎
90Theophylline(휇g/mL) − − − − − − − −
− −
Figure 7: Ginkgo extracts increase intracellular cAMP level in
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statistically signiﬁcant only for G24. Our results seem to cor-
roborate the hypothesis that cAMP may negatively regulate
E-selectin transcription/surface expression and VCAM-1
surface expression acting on the NF-κB system. On the con-
trary, cAMP elevation may have an opposite eﬀect on ICAM-
1 inhibition. Remarkably, the increase of cAMP following 6
hours of treatment with G24 or G4E paralleled the loss of
inhibitory eﬀect on ICAM-1 transcription. Indeed, our ﬁnd-
ings are partially conﬁrmed by other authors demonstrating
that EGB761 extract preferentially inhibits PDE type 4 in
HUVECs [38]; in this study performed in primary HUVECs,
the extract was eﬀective at lower concentrations thus suggest-
ing that immortalized endothelial cells used in the present
study may be less sensitive to the pharmacological eﬀects of
the extract. Moreover, it has been previously demonstrated
that ginkgolide C (10-500 μM) is able to increase cAMP
and cGMP in platelets [39]. Our results, in addition to those
occurring in the literature, suggest for the ﬁrst time that inhi-
bition of E-selectin by Ginkgo biloba extracts in HUVECs
may be due, at least in part, to cAMP elevation resulted
by PDE inhibition; indeed, it has been previously reported
that ginkgo constituents are inhibitors of cGMP- and
cAMP-dependent phosphodiesterase [40] [41]. In addition,
ginkgo leaf extracts may impair NF-κB through AMPK
activation [32]. It has been demonstrated that other phos-
phodiesterase inhibitors, such as cilostazol, activate AMPK
pathway, which may lead to the impairment of proinﬂam-
matory adhesion molecules in platelets and endothelial cells
(Figure 8) [42, 43].
Concentrations used in the present research may be con-
sidered high and not easily reachable in vivo; however, it has
been previously reported that ginkgolides and bilobalide are
able to be absorbed in vivo, reaching signiﬁcant concentra-
tions in blood, according to EMA monograph [21]. Bioavail-
ability of ginkgo ﬂavonoids including kaempferol and
quercetin is still controversial. Although variability exists
within diﬀerent formulations, it has been reported that ginkgo
ﬂavonoids are absorbed and reach the plasma and brain in
detectable amounts in vivo whereas other authors detect only
the corresponding glucuronides [44–47]. Taken together,
these results allow to hypothesize that in addition to lactones,
ﬂavonoids or their metabolites could eﬃciently show biologi-
cal activity in endothelial cells [13]. In addition, synergistic
eﬀects among ginkgo active compounds cannot be excluded.
4. Conclusions
European Pharmacopoeia recommends extraction of Ginkgo
powder with acetone; our ﬁndings demonstrate for the ﬁrst
time that ethanol (G4E) and acetone (G24) extracts show
comparable anti-inﬂammatory and antioxidant activity in
human endothelial cells. In some countries, including Japan,
solvents allowed in food supplements or plant extracts are
limited to ethanol, thus implying that the usage of standard-
ized ethanol extracts is mandatory. Thus, the results reported
herein show that ginkgo extracts made from extraction with
acetone or ethanol exhibit similar anti-inﬂammatory and
antioxidant activities, providing new insights into the usage
of ethanol extracts in those countries where restrictions in
amount of acetone are present. However, diﬀerent eﬀects of
the extracts on other pathways cannot be excluded.
This work clariﬁes the mode of action by which ginkgo
extracts inhibit adhesion molecules acting on diﬀerent steps
of the NF-κB pathway increasing cAMP levels in human
endothelial cells.
Concentrations of the extracts used in the present
work may be reached in vivo since lactones, particularly
ginkgolides, are adsorbed and reach blood at signiﬁcant
concentrations thus contributing to the biological eﬀects
reported herein.
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Figure 8: Proposed mechanism to explain the eﬀect of ginkgo extracts on signaling cascade involved in E-selectin regulation. Ginkgo could
reduce the NF-κB activation by increasing intracellular cAMP levels acting on PDE4 or by enhancing AMPK activity. Lines with arrows
indicate activation, while lines with bars indicate inhibition.
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